Cargando…
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The International AIDS Society
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113075/ http://dx.doi.org/10.1186/1758-2652-13-S4-P7 |
| _version_ | 1782205882247938048 |
|---|---|
| author | Kumar, P DeJesus, E Huhn, G Sloan, L Garcia, F Small, C Edelstein, H Felizarta, F Hao, R Ha, B Stancil, B Ross, L Oie, K Pappa, K |
| author_facet | Kumar, P DeJesus, E Huhn, G Sloan, L Garcia, F Small, C Edelstein, H Felizarta, F Hao, R Ha, B Stancil, B Ross, L Oie, K Pappa, K |
| author_sort | Kumar, P |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3113075 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | The International AIDS Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-31130752011-06-13 SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients Kumar, P DeJesus, E Huhn, G Sloan, L Garcia, F Small, C Edelstein, H Felizarta, F Hao, R Ha, B Stancil, B Ross, L Oie, K Pappa, K J Int AIDS Soc Poster Presentation The International AIDS Society 2010-11-08 /pmc/articles/PMC3113075/ http://dx.doi.org/10.1186/1758-2652-13-S4-P7 Text en Copyright ©2010 Ha et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Kumar, P DeJesus, E Huhn, G Sloan, L Garcia, F Small, C Edelstein, H Felizarta, F Hao, R Ha, B Stancil, B Ross, L Oie, K Pappa, K SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients |
| title | SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients |
| title_full | SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients |
| title_fullStr | SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients |
| title_full_unstemmed | SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients |
| title_short | SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients |
| title_sort | support: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113075/ http://dx.doi.org/10.1186/1758-2652-13-S4-P7 |
| work_keys_str_mv | AT kumarp support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT dejesuse support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT huhng support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT sloanl support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT garciaf support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT smallc support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT edelsteinh support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT felizartaf support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT haor support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT hab support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT stancilb support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT rossl support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT oiek support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients AT pappak support48weekresultsoffosamprenavirritonavirvsefavirenzwithabacavirlamivudineinunderrepresentedantiretroviralnaivepatients |